Yu Jing, Hou Liqiang, Fan Libei, Wang Haomin, Jin Xianzheng, Zhou Haifeng
Department of Orthopedics, Zhejiang Jinhua Guangfu Cancer Hospital, Jinhua City, Zhejiang Province, China.
Department of Orthopedics, Zhejiang Jinhua Guangfu Cancer Hospital, Jinhua City, Zhejiang Province, China.
Orthop Traumatol Surg Res. 2025 May;111(3):104035. doi: 10.1016/j.otsr.2024.104035. Epub 2024 Nov 4.
The management of antiplatelet therapy (APT) in patients undergoing spinal surgery is complex, requiring balancing the risks of thromboembolic events against those of potential perioperative bleeding. This review evaluates the effects of continuing versus discontinuing APT on the surgical outcomes of spinal surgery.
The hypothesis is that continuing antiplatelet therapy (APT) in patients undergoing spinal surgery will not significantly increase intraoperative blood loss, operative time, or postoperative complications compared to discontinuing APT, but may lead to a higher need for postoperative transfusions.
Systematic search was done in EMBASE, Scopus, PubMed Central, Google Scholar, and ScienceDirect databases for studies comparing the continuation of APT to its discontinuation in terms of estimated blood loss, operative time, hospital stay length, postoperative transfusion units, postoperative complications, postoperative hematoma, readmission rate, cardiovascular events amongst patients undergoing spinal surgery. Risk of bias was assessed with the Newcastle Ottawa scale and synthesized the data using random-effects meta-analyses, summarizing outcome results as either standardized mean differences (SMDs) or odds ratios (ORs) as appropriate.
13 studies were included in meta-analysis. Similar estimated blood losses (SMD = 0.125; 95%CI, -0.087 to 0.337) and operative times (SMD = 0.231; 95%CI, -0.225 to 0.687) were found between the patients who continued and those who discontinued the APT. However, patients who continued APT had a slightly higher chance of requiring postoperative transfusions (SMD = 0.244; 95%CI, 0.030 to 0.458). Similar hospital stay lengths, and postoperative complication or cardiovascular event rates were found.
Continuing APT during spinal surgery does not significantly increase the risks of intraoperative blood loss or increase the operative time, however; it may increase the need for postoperative transfusions. These findings suggest that for patients at risk of thromboembolic events, the benefits of continuing APT outweigh the risks.
III; Systematic Review and Meta-analysis.
脊柱手术患者抗血小板治疗(APT)的管理较为复杂,需要在血栓栓塞事件风险与围手术期潜在出血风险之间进行权衡。本综述评估了继续与停用APT对脊柱手术手术结局的影响。
假设是与停用APT相比,脊柱手术患者继续抗血小板治疗(APT)不会显著增加术中失血量、手术时间或术后并发症,但可能导致术后输血需求增加。
在EMBASE、Scopus、PubMed Central、谷歌学术和ScienceDirect数据库中进行系统检索,以查找比较脊柱手术患者继续与停用APT在估计失血量、手术时间、住院时间、术后输血量、术后并发症、术后血肿、再入院率、心血管事件方面的研究。使用纽卡斯尔渥太华量表评估偏倚风险,并采用随机效应荟萃分析对数据进行综合分析,根据情况将结局结果总结为标准化均数差(SMD)或比值比(OR)。
13项研究纳入荟萃分析。继续和停用APT的患者之间估计失血量(SMD = 0.125;95%CI,-0.087至0.337)和手术时间(SMD = 0.231;95%CI,-0.225至0.687)相似。然而,继续APT的患者术后输血的可能性略高(SMD = 0.244;95%CI,0.030至0.458)。住院时间、术后并发症或心血管事件发生率相似。
脊柱手术期间继续APT不会显著增加术中失血风险或延长手术时间,然而,可能会增加术后输血需求。这些发现表明,对于有血栓栓塞事件风险的患者,继续APT的益处大于风险。
III;系统评价与荟萃分析。